Personalized oncology and BRAF^K601N melanoma: model development, drug discovery, and clinical correlation.

ABSTRACT:

Purpose

Mutations in BRAF are the most prominent activating mutations in melanoma and are increasingly recognized in other cancers. There is currently no accepted treatment regimen for patients with mutant BRAF^K601N melanoma, and the study of melanoma driven by BRAF mutations at the 601 locus is lacking due to a paucity of cellular model systems. Therefore, we sought to better understand the treatment and clinical approach to patients with mutant BRAF^K601N melanoma and subsequently develop a novel personalized oncology platform for rare or treatment-refractory cancers.

Methods

We developed and characterized the first patient-derived, naturally occurring BRAF^K601N melanoma model, described herein as OHRI-MEL-13, and assessed efficacy using the

SUBMITTER: Keller BA 

PROVIDER: S-EPMC11802029 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature